| Description | BL-002-1250containsaproprietarymixtureofproteinsandbufferreagentsdesignedtoreduceheterophilicinteractionsinELISAassaysutilizingmouseImmunoReagents. FollowingELISAassaysintheBiosensisRapidTMELISArangehavebeenvalidatedtoachieveaccurateresultsusingBL-002-1250: BEK-2219,HumanNGFR/p75ECD;Application:Serum,Citrate-Plasma,CSF,Urine. OnevialofBL-002-1250contains1250µgIgGwhichissufficientassamplediluentadditiveforone96-wellplate. OtherELISAassaysthatusemouseassayantibodiesmayalsobenefitfromadditionofblockerBL-002-1250,butrequireoptimizationofworkingconcentrationandassayvalidationforaccurateresults. |
| Relatedproducts | BEK-2219-1P,HumanNGFR/p75ECDRapidTMELISA BEK-2219-2P,HumanNGFR/p75ECDRapidTMELISA |
| BatchNo. | Seeproductlabel. |
| Unitsize | 1250µg |
| Applications | ImmunoassayblockertoreduceoreliminateheterophilicantibodyinterferenceinsandwichELISAassaysforvalidatedsampleapplications. |
| Form | Lyophilized. |
| Appearance | Whitepowder. |
| Reconstitution | 1)Reconstitutewith1mLassaydiluentbuffertoachieveablockerstockconcentrationof1.25mg/mL. 2)Dilutethisstockbufferfurtherwith24mLassaydiluentbuffertoobtaintheblockerworkingconcentrationof50µg/mL.RefertoRapidTMELISAkitprotocolforfurtherdetails. TheworkingconcentrationofthisHAblockerneedstobeoptimizedbytheend-userforotherELISAassays. |
| Storage | Storeunopenedvialat2-8°C. |
| ExpiryDate | 12monthsafterpurchase(unopenedvial). |
| Kitprotocol |
Biosensis专注于神经科学领域的抗体和试剂的开发,特别是神经营养因子和神经营养因子受体。 近30年来,Biosensis一直是该领域的全球领航者和OEM供应商。除神经营养因子,我们的神经科学产品组合还被广泛用于神经退行性疾病、神经发育和神经代谢的研究。重点研究领域包括阿尔茨海默氏症(AD)、帕金森氏症(PD)和肌萎缩侧索硬化(ALS)疾病,以及自噬和代谢应激障碍,包括肥胖、代谢综合征的研究、神经免疫学和炎症。



